index,Regulator Name,Regulator Type,Regulator Subtype,Regulator HGNC Symbol,Regulator Database,Regulator ID,Regulator Compartment,Regulator Compartment ID,Regulated Name,Regulated Type,Regulated Subtype,Regulated HGNC Symbol,Regulated Database,Regulated ID,Regulated Compartment,Regulated Compartment ID,Sign,Connection Type,Mechanism,Site,Cell Line,Cell Type,Tissue Type,Organism,Unnamed: 0,Score,Source,Statements,Paper IDs,Evidence Score,Match Score,Kind Score,Epistemic Value,Total Score
73,il-2,protein,,,uniprot,p60568,plasma membrane,go:0005886,s6,protein,,rps6,uniprot,p62753,cytoplasm,go:0005737,positive,i,phosphorylation,,,t-cell,,human,['28'],nan,nan,"however, il-2 activates multiple intracellular pathways in addition to stat5-mediated signaling, including mitogen-activated protein kinase (mapk) and pi3k–akt–mtor pathways (boyman and sprent, 2012; liao et al., 2013). surprisingly, despite their increased phosphorylation of stat5, itk-deficient cells showed less il-2–induced phosphorylation of s6, suggesting reduced mtor activation compared with wt cells (fig. 6 c). similar results were observed when cells were initially stimulated under itreg cell conditions with low concentrations of anti-cd3, so that wt and itk-deficient cells had equivalent percentages of foxp3+ cells (not depicted). these results suggest that itk deficiency did not simply increase il-2 responses, but rather altered signaling in response to il-2, such that stat5 activation was uncoupled from mtor activation.",pmc3949578,1,10,5,1,15
154,mtorc1,proteincomplex,,,uniprot,,cytoplasm,go:0005737,mtorc2,proteincomplex,,,uniprot,,cytoplasm,go:0005737,negative,i,inhibition,downstream molecules,,cancer cells,hematological malignancies,human,['119'],nan,nan,"many previous reports have shown that mtorc1 and mtorc2 represent a promising therapeutic target in a number of cancers and hematological malignancies.43 rapamycin and its derivatives (rapalogs) have been clinically approved for renal transplantation, advanced renal cell carcinoma, and other purposes.44 however, the clinical efficacy of these drugs is somehow limited when used as a single agent for anti‐cancer therapy. several factors may explain this lack of efficacy. for example, the rapalogs cannot completely block the phosphorylation of mtorc1 substrates, especially when the phosphorylation of 4e‐bp is insensitive to them. both rapamycin and rapalogs also suppresses the negative‐feedback loop of molecules downstream from mtorc1, including s6k and grb10.45, 46 this results in the activation of akt and paradoxically promotes cell growth.47 moreover, as mtorc1 also negatively regulates mtorc2, rapamycin and the rapalogs lower inhibition against mtorc2, resulting in compensatory akt activation by mtorc2. we herein demonstrate that the mtorc1 inhibitors induce cell‐cycle arrest but not apoptosis in atl cells. everolimus inhibited the growth of atl‐cell xenografts at first, but after the dosing was completed, the tumor cells might be recruited into the cell cycle again, resulting in progressive growth similar to the control group. we suggest that this cytostatic but not cytotoxic effect might be attributable to activation of akt.",pmc5765289,1,10,5,1,15
211,pten,protein,,pten,uniprot,p60484,cell membrane,go:0016020,pi3k,protein,,pik3ca,uniprot,p42336,cell membrane,go:0016020,negative,i,suppressor,,,,,,['199'],nan,nan,suppressor in a pi3k-independent manner. pten loss of function due to gene mutations,pmc5986278,1,10,5,1,15
224,pten,protein,,pten,uniprot,p60484,cytoplasm,go:0005737,pi3k,protein,,pik3ca,uniprot,p42336,plasma membrane,go:0005886,negative,i,affects,,human t-all,t-cell,,human,['243'],nan,nan,"human t-all cell lines, we hypothesized that the pten/pi3k pathway affects the",pmc5986278,1,10,5,1,15
237,pten,protein,,pten,uniprot,p60484,,,pi3k,protein,,,,,,,negative,i,buffering,,,,,,['173'],nan,nan,"the phosphatase and tensin homolog (pten) was originally discovered as a candidate tumor suppressor mutated and lost in various cancers. the major role of pten is the buffering molecular of pi3k signaling pathway.[17,18] yet recent studies point to additional novel, lipid phosphatase-independent functions that may contribute to its tumor-suppressive activity.[17,19] the function of pten in various tumor has been reported. previous report indicated that notch signaling and pi3k/akt pathway act synergistically to maintain oncogenic activity in t-cell acute lymphoblastic leukemia.[20,21] pi3k/akt was found activated in microarray analysis of nk/t cell lymphoma (nktcl), and nuclear expression of phosphorylated-akt was found in the nucleus of most nktcl samples.[22] data on pten pathway in chinese population and its clinical value, are relatively limited.",pmc5521878,1,10,5,1,15
188,pi3k p110δ,protein,,pik3cd,uniprot,o00329,,,pi3kδ,protein,,pik3cd,uniprot,o00329,,,positive,i,,,,leukocytes,,,['198'],nan,nan,highly enriched in leukocytes. pi3k p110δ (pi3kδ) is encoded by,pmc5986278,1,10,1,1,11
